Trials / Conditions / NK/T Cell Lymphoma

NK/T Cell Lymphoma

24 registered clinical trials studyying NK/T Cell Lymphoma — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768	Rong Tao	Phase 1 / Phase 2
Not Yet Recruiting	Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL NCT07457177	LIANG WANG	Phase 2
Not Yet Recruiting	Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic NCT07276698	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 2
Not Yet Recruiting	Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic St NCT07276737	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 2
Recruiting	Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	EARLY_Phase 1
Recruiting	A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients W NCT07000617	Peking University Cancer Hospital & Institute	Phase 2
Recruiting	RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 1
Recruiting	Circulating Tumor DNA in Peripheral T-cell Lymphomas NCT06362148	University of Aarhus	—
Recruiting	PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma NCT05662540	Ruijin Hospital	N/A
Recruiting	Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893	Chinese PLA General Hospital	Phase 2
Active Not Recruiting	A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL NCT05627856	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 / Phase 2
Unknown	An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD3 NCT05208853	Zhejiang University	EARLY_Phase 1
Unknown	Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma NCT04899414	Peking University	Phase 2
Terminated	A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Mo NCT04425070	Antengene Corporation	Phase 1 / Phase 2
Withdrawn	Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma NCT04230330	National Cancer Centre, Singapore	Phase 1
Unknown	CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic L NCT04004637	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Phase 1
Unknown	Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies NCT04008394	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 1
Unknown	PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma NCT04038411	Mingzhi Zhang	Phase 4
Unknown	PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma NCT03701022	Peking University	Phase 2
Completed	Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types NCT03012620	UNICANCER	Phase 2
Unknown	A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma NCT04490590	Mingzhi Zhang	Phase 4
Completed	A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymp NCT02588651	Deepa Jagadeesh	Phase 2
Completed	Gemcitabine in NK/T Cell Lymphoma NCT01660568	Samsung Medical Center	—
Completed	Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas NCT01445535	National Cancer Institute (NCI)	Phase 1